minoxidil has been researched along with methotrexate in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alkhalifah, A; Alsantali, A; McElwee, KJ; Shapiro, J; Wang, E | 1 |
| Shapiro, J | 1 |
| Fabi, SG; Zaleski-Larsen, LA | 1 |
| Avila, L; Brinster, N; Christiano, AM; Lo Sicco, K; Shapiro, J; Strazzulla, LC; Wang, EHC | 1 |
| Atallah, RB; Eldahshan, RM; Toma, DM | 1 |
5 review(s) available for minoxidil and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Alopecia areata update: part II. Treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia Areata; Animals; Child; Cyclopropanes; Cyclosporine; Hair; Haptens; Humans; Immunotherapy; Injections, Intralesional; Laser Therapy; Methotrexate; Minoxidil; Photochemotherapy; Randomized Controlled Trials as Topic; Rats; Recurrence; Research Design; Social Support; Sulfasalazine; Treatment Outcome; Triamcinolone Acetonide | 2010 |
Current treatment of alopecia areata.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Alopecia Areata; Anthralin; Cyclobutanes; Cyclopropanes; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Injections, Intralesional; Methotrexate; Minoxidil; PUVA Therapy; Self-Help Groups | 2013 |
Laser-Assisted Drug Delivery.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Aminolevulinic Acid; Aminoquinolines; Analgesics; Antibodies; Antineoplastic Agents; Ascorbic Acid; Cyclopropanes; Dermatologic Agents; Drug Delivery Systems; Fluorouracil; Humans; Imiquimod; Immunotherapy; Laser Therapy; Methotrexate; Minoxidil; Permeability; Photosensitizing Agents; Polyesters; RNA, Small Interfering; Skin; Timolol; Vaccines | 2016 |
Alopecia areata: An appraisal of new treatment approaches and overview of current therapies.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Alopecia Areata; Dermatologic Agents; Education, Medical, Continuing; Female; Humans; Immunotherapy; Injections, Intralesional; Male; Methotrexate; Minoxidil; Quality of Life; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2018 |
1 trial(s) available for minoxidil and methotrexate
| Article | Year |
|---|---|
Comparative study between topical methotrexate 1% gel and minoxidil 5% gel in the treatment of localized alopecia areata.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Gels; Humans; Methotrexate; Minoxidil; Treatment Outcome | 2022 |
10 other study(ies) available for minoxidil and methotrexate
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |